ASP Isotopes said it has moved “from development into early commercialization” over the past 12 months, and it pointed to several operating milestones now feeding into revenue growth.
The company said 2026 marks a transition “from building to producing,” with two near-term drivers expected over the next 12 months: higher revenue from liquid helium production as Phase 1 is completed, and continued growth in its radiopharmacies. It also said it expects its first commercial shipments from its stable isotope division in the same period.
Management said those steps are part of a plan to reach more than $300 million of EBITDA in 2031.
The company also said it is continuing to pursue public listings for Quantum Leap Energy and Noble Africa as separate public companies.
ASP Isotopes did not provide numerical revenue, shipment, or customer figures in the release, but it emphasized that the past year has shifted the business from development toward commercial activity across nuclear medicine, electronics, helium and LNG, and nuclear fuels.
The company said detailed updates on each business were being presented at its inaugural capital markets day in London. Today the company's shares have moved 4.72% to a price of $4.3981. If you want to know more, read the company's complete 8-K report here.
